Cargando…

Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma

Multiple myeloma grows by establishing multiple interactions with bone marrow cells. These include expansion of myeloid-derived suppressor cells, which drive immunoevasion via mechanisms that include arginase-1-driven depletion of L-arginine, thus indirectly promoting myeloma cell survival and tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trudu, Matteo, Oliva, Laura, Orfanelli, Ugo, Romano, Alessandra, Di Raimondo, Francesco, Sanvito, Francesca, Ponzoni, Maurilio, Cenci, Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512038/ https://www.ncbi.nlm.nih.gov/pubmed/36172163 http://dx.doi.org/10.3389/fonc.2022.968208

Ejemplares similares

P852: ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMA CELLS
por: Romano, Alessandra, et al.
Publicado: (2023)

Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
por: Romano, Alessandra, et al.
Publicado: (2021)

P870: DEFINING A NOVEL FUNCTION FOR THE POST-TRANSLATIONAL MODIFICATION UFMYLATION IN THE ADAPTIVE RESPONSE TO ARGININE DEPRIVATION IN MULTIPLE MYELOMA
por: Romano, A., et al.
Publicado: (2022)

L-Canavanine potentiates the cytotoxicity of doxorubicin and cisplatin in arginine deprived human cancer cells
por: Nurcahyanti, Agustina DR, et al.
Publicado: (2016)

P02 ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMACELLS
por: Romano, A., et al.
Publicado: (2023)

P042: Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2022)

Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies
por: Lazzari, Chiara, et al.
Publicado: (2023)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma
por: Slomp, Anne, et al.
Publicado: (2018)

Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
por: Duminuco, Andrea, et al.
Publicado: (2023)

A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells
por: Milan, Enrico, et al.
Publicado: (2015)

P01: ARGININE STARVATION IN MULTIPLE MYELOMA MICROENVIRONMENT CONVEYS BORTEZOMIB REFRACTORINESS VIA TLR4 PATHWAY.
por: Romano, A, et al.
Publicado: (2022)

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
por: Markovic, Uros, et al.
Publicado: (2021)

Arginine deprivation therapy for malignant melanoma
por: Yoon, Jung-Ki, et al.
Publicado: (2012)

Selective Preservation of Bone Marrow Mature Recirculating but Not Marginal Zone B Cells in Murine Models of Chronic Inflammation
por: Traggiai, Elisabetta, et al.
Publicado: (2010)

Optimizing arginine deprivation for hard-to-treat cancers
por: Khadeir, Ramsay, et al.
Publicado: (2017)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022)

Bench-to-Bedside Studies of Arginine Deprivation in Cancer
por: Field, George C., et al.
Publicado: (2023)

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
por: Bertamini, Luca, et al.
Publicado: (2022)

Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
por: Bolli, Niccolo, et al.
Publicado: (2020)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

L-Arginine in diabetes: clinical and preclinical evidence
por: Forzano, Imma, et al.
Publicado: (2023)

Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy
por: Kim, Sun-Hee, et al.
Publicado: (2018)

Targeted Arginine Metabolism Therapy: A Dilemma in Glioma Treatment
por: Hou, Xiaoshuang, et al.
Publicado: (2022)

Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors
por: Hajji, Nabil, et al.
Publicado: (2022)

A wholesale approach to disarm multiple myeloma
por: Cenci, Simone
Publicado: (2023)

Correction: L-Arginine in diabetes: clinical and preclinical evidence
por: Forzano, Imma, et al.
Publicado: (2023)

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
por: Savaraj, Niramol, et al.
Publicado: (2007)

Deprivation of arginine by recombinant human arginase in prostate cancer cells
por: Hsueh, Eddy C, et al.
Publicado: (2012)

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
por: Li, Ying-Ying, et al.
Publicado: (2016)

Argininosuccinate synthase 1, arginine deprivation therapy and cancer management
por: Sun, Naihui, et al.
Publicado: (2022)

Preclinical Models of Malignant Mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2020)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
por: Antonioli, Elisabetta, et al.
Publicado: (2023)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

HGG-13. Combined CDK inhibition and arginine-deprivation as targeted therapy for arginine-auxotrophic glioblastoma multiforme cells
por: Riess, Christin, et al.
Publicado: (2022)

Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells
por: Riess, Christin, et al.
Publicado: (2022)

The pro-tumorigenic cytokine IL-32 has a high turnover in multiple myeloma cells due to proteolysis regulated by oxygen-sensing cysteine dioxygenase and deubiquitinating enzymes
por: Kastnes, Martin, et al.
Publicado: (2023)

The Coming of Age of Preclinical Models of MDS
por: Liu, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5e8f0t2ev6bj5gfd815iejra5v